Navigation Links
Many solid tumors carry genetic changes targeted by existing compounds
Date:5/31/2013

CHICAGO, IL (May 28, 2013)Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3. The results suggest that it may one day become commonplace for doctors to sequence tumors before deciding on a treatment regimen.

"Extended sequencing of a patient's tumor is not something that's routinely done now," says study author Patrick Boland, MD, a hematology/oncology fellow at Fox Chase. "Our ultimate hope is that, if we determine testing is worthwhile, it becomes routine for a doctor to send off a tumor sample to look for mutations before deciding on a course of treatment."

In some forms of cancer, such as lung cancer, doctors do check for a limited number of mutations. Mutations found with this focused testing only affect the treatment of a small proportion of patients. However, most tumors likely have many mutations, some of which may be targeted specifically by drugs already on the market, or under development.

To investigate, 77 patients with solid tumorsprimarily inflammatory breast cancer and colon cancer underwent genetic profiling looking for nearly 200 mutations associated with cancer. Boland and his co-author Alan Skarbnik reviewed the DNA sequencing to analyze the net results of testing and consider the potential impact on patient care.

Most of the patients96%carried one mutation or more. Nearly two-thirds had at least one mutation the researchers termed "actionable," meaning it is targeted by a drug that is on the market or in development. Many of the mutations were amplifications, in which multiple copies of a single gene were present, which ramps up its effect on the body.

Boland stresses that even though these genetic alterations are present, in many cases it's not clear which ones if any are driving the cancers. "Even if we find a [change], we don't know if it's something that's driving the tumor to grow, or something that just happened along the way." The results from this study highlight the need for more research to understand the basic biology of tumors, he notes. "We need our colleagues in the basic sciences to continue investigating the genetic underpinnings of cancer, so we can determine which mutations are most important to target."

The sequenced data was reviewed by the patients' doctors, and in some cases, they prescribed new medications that targeted the identified mutations. Even though patients had all triedand failedtreatments in the past, some responded well to the new medicine, including one patient who has been on the treatment for at least 6 months.

A major limiting factor in sequencing all tumors, says Boland, is costthe list price of the sequencing test used in the study, from the company Foundation Medicine, is nearly $6,000. "We hope that, once sequencing tumors becomes the standard of care, it will be routinely covered by insurance."

Indeed, genetic sequencing is getting more affordable, notes Boland. Once tumor DNA can be analyzed readily, doctors learn more regarding how to use that information to guide treatment, and patients get more access to medicines that target these mutations which may be beneficial. It may become commonplace for most doctors to sequence tumors before deciding how to treat them. "The expectation is that, sometime soon, these kinds of tests will be done on a routine basis," predicts Boland. "We're not there yet."


'/>"/>
Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. New Jersey Court Consolidates Statewide Mirena IUD Lawsuits, Rottenstein Law Group LLP Reports
2. Stryker Rejuvenate Attorneys at Kershaw, Cutter & Ratinoff Push for Cases to be Consolidated and Fought in U.S. District Court in Chicago, Illinois
3. Stryker Hip Recall Lawyers at Gilman Law LLP Look Forward to Upcoming Hearing on Stryker Rejuvenate and ABG II Hip Lawsuit Consolidation
4. Cymbet EnerChip Solid State Batteries Verified 100% Biocompatible
5. Smith & Nephew Hip Recall News: Bernstein Liebhard LLP Notes Motion to Consolidate Smith & Nephew Lawsuits Filed in Tennessee State Courts
6. Solid-state controllable light filter may protect preterm infants from disturbing light
7. Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Some CasesDismissed from Consolidated Litigation
8. New Instrument for High-Precision Measurements of Soy Milk Solids and Protein Concentration
9. Consolidated Facility Advises Spring Cleaning Done Now in Davis Businesses
10. AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
11. Researchers to develop next generation immunotherapy for children with deadly solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) ... Friday, March 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has ... the South Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... healthcare automation intelligence company based in New York. , “Ensuring an intuitive, user-friendly ... workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition is ...
(Date:2/28/2017)... ... 2017 , ... The role of females in the military, ... civilian life. Body image dissatisfaction is largely unexamined among female veterans, a rapidly ... of chronic mental health conditions than female civilians. Female veterans also are more ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 2017 Research and Markets has announced ... 2014-2025" report to their offering. ... The global digestive enzyme ... 2025. Growing consumer awareness regarding the severity of digestive disorders ... stimulate industry growth over the forecast period. The increasing incidence ...
(Date:2/28/2017)... , Feb 28, 2017 ... Research and Markets has ... report to their offering. The global orthobiologics ... The orthobiologics market is predominantly driven by the ... innovations in biomaterials, used in the production of orthobiologics are presumed ...
(Date:2/27/2017)... Health, Inc. (NYSE: HYH ) today reported fourth ... and related key planning assumptions. Executive Summary 2016 ... increase compared to the prior year. Net ... to net income of $15 million in the fourth quarter ... compared to adjusted net income of $27 million in the ...
Breaking Medicine Technology: